Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence.
Publication
, Journal Article
Sarker, J; Atallah, EL; Flynn, KE; Winn, AN
Published in: Leuk Lymphoma
August 2025
Duke Scholars
Published In
Leuk Lymphoma
DOI
EISSN
1029-2403
Publication Date
August 2025
Volume
66
Issue
8
Start / End Page
1515 / 1520
Location
United States
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Sarker, J., Atallah, E. L., Flynn, K. E., & Winn, A. N. (2025). Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence. Leuk Lymphoma, 66(8), 1515–1520. https://doi.org/10.1080/10428194.2025.2482133
Sarker, Jyotirmoy, Ehab L. Atallah, Kathryn E. Flynn, and Aaron N. Winn. “Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence.” Leuk Lymphoma 66, no. 8 (August 2025): 1515–20. https://doi.org/10.1080/10428194.2025.2482133.
Sarker J, Atallah EL, Flynn KE, Winn AN. Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence. Leuk Lymphoma. 2025 Aug;66(8):1515–20.
Sarker, Jyotirmoy, et al. “Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence.” Leuk Lymphoma, vol. 66, no. 8, Aug. 2025, pp. 1515–20. Pubmed, doi:10.1080/10428194.2025.2482133.
Sarker J, Atallah EL, Flynn KE, Winn AN. Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence. Leuk Lymphoma. 2025 Aug;66(8):1515–1520.
Published In
Leuk Lymphoma
DOI
EISSN
1029-2403
Publication Date
August 2025
Volume
66
Issue
8
Start / End Page
1515 / 1520
Location
United States
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences